Kilickap, S.Ozturk, A.Karadurmus, N.Korkmaz, T.Yumuk, P.Cicin, I.Paydas, S.Cilbir, E.Sakalar, T.Uysal, M.Uskent, N.Demir, N.Sakin, A.Turhal, N.Keskin, S.Tural, D.Eralp, Y.Basal, F.Yasar, H.Sendur, M. A.Demirci, U.Cubukcu, E.Karaagac, M.Karaca, S.Tatli, A.Yetisyigit, T.Urvay, S.Gursoy, P.Uluc, B. OyanTurna, Z.Kucukoner, M.Olmez, O.Cabuk, D.Seker, M.Unal, O.Meydan, N.Okutur, S.Tunali, D.2019-10-272019-10-2720181556-08641556-1380https://hdl.handle.net/11454/29848eninfo:eu-repo/semantics/closedAccessNSCLCALK inhibitorcrizotinibCrizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from TurkeyConference Object1310S477S478WOS:000454014501235Q1